Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cancer Manag Res
2020 Jan 24;12:589-598. doi: 10.2147/CMAR.S229217.
Show Gene links
Show Anatomy links
Clinicopathological and Prognostic Significance of EML4-ALK Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study.
Shi J
,
Gu W
,
Zhao Y
,
Zhu J
,
Jiang G
,
Bao M
,
Shi J
.
???displayArticle.abstract???
OBJECTIVE: The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is a key oncogenic driver in non-small cell lung cancer (NSCLC). This study analyzed the clinicopathological characteristics and prognostic significance of EML4-ALK fusion gene in patients with surgically resected adenocarcinoma.
METHODS: The clinicopathological characteristics of 1056 consecutive patients with surgically resected stage I-IIIA adenocarcinoma were collected from February 2014 to October 2014, and EML4-ALK rearrangement was detected using real-time polymerase chain reaction (RT-PCR) technology. To compare the imaging and pathological features, a propensity score matching (PSM) method was performed. The follow-up information was collected to evaluate the long-term outcomes of patients with EML4-ALK rearrangement.
RESULTS: The prevalence of EML4-ALK rearrangement was 6.6% in 1056 consecutive patients. A total of 70 EML4-ALK-positive and 210 EML4-ALK-negative patients were identified after PSM. Imaging and pathological analyses showed that EML4-ALK rearrangement was significantly associated with less ground-glass opacity (GGO) (adjusted OR=1.38, 95% CI=1.03-1.85, Ptrend =0.029) and higher prevalence of non-invasive mucinous adenocarcinoma mucin-laden adenocarcinomas (non-IMA MLA, adjusted OR=6.79, 95% CI=2.69-17.17, P<0.001). EML4-ALK rearrangement was found to be an unfavorable prognostic factor for disease-free survival (DFS) in female patients (HR=2.26, 95% CI=1.13-4.53, P=0.021).
CONCLUSION: Our results suggest that adenocarcinomas harboring EML4-ALK fusion gene exhibit specific radiological and pathological characteristics compared with EML4-ALK-negative adenocarcinomas. In female patients, EML4-ALK rearrangement was associated with shorter DFS.
Blackhall,
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
2014, Pubmed
Blackhall,
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
2014,
Pubmed
Cancer Genome Atlas Research Network,
Comprehensive molecular profiling of lung adenocarcinoma.
2014,
Pubmed
Chaft,
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
2018,
Pubmed
D'Angelo,
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
2012,
Pubmed
Ebright,
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.
2002,
Pubmed
Fukui,
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.
2012,
Pubmed
,
Echinobase
Gao,
Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement.
2017,
Pubmed
Hsu,
Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma.
2014,
Pubmed
Inamura,
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
2008,
Pubmed
,
Echinobase
Jeon,
Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
2015,
Pubmed
Kim,
Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
2016,
Pubmed
Kim,
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
2014,
Pubmed
Kometani,
Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
2018,
Pubmed
Lindeman,
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
2018,
Pubmed
Liu,
CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
2016,
Pubmed
Liu,
Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer.
2014,
Pubmed
,
Echinobase
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Paik,
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
2012,
Pubmed
Park,
Malignant pure pulmonary ground-glass opacity nodules: prognostic implications.
2009,
Pubmed
Ren,
Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
2012,
Pubmed
Rodig,
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
2009,
Pubmed
Shaw,
ALK in lung cancer: past, present, and future.
2013,
Pubmed
Shin,
Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma.
2018,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Solomon,
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
2018,
Pubmed
Sugano,
Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma.
2011,
Pubmed
Suh,
Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study.
2018,
Pubmed
Takahashi,
Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
2010,
Pubmed
,
Echinobase
Travis,
Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification.
2011,
Pubmed
Wang,
Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis.
2017,
Pubmed
Yang,
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
2012,
Pubmed
Yang,
EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
2015,
Pubmed
Yoshida,
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
2016,
Pubmed
Yoshida,
Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
2011,
Pubmed
Zhao,
Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
2015,
Pubmed
,
Echinobase
Zhou,
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
2013,
Pubmed
